Isolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probiotics

Página do item simplificado
dc.contributor.authorCeliberto, Larissa S. [UNESP]
dc.contributor.authorPinto, Roseli Aparecida [UNESP]
dc.contributor.authorRossi, Elizeu Antonio [UNESP]
dc.contributor.authorVallance, Bruce A.
dc.contributor.authorCavallini, Daniela C U [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionBC Children's Hospital and the University of British Columbia
dc.date.accessioned2019-10-06T16:04:40Z
dc.date.available2019-10-06T16:04:40Z
dc.date.issued2018-11-05
dc.description.abstractModulation of the gut microbiota through the use of probiotics has been widely used to treat or prevent several intestinal diseases. However, inconsistent results have compromised the efficacy of this approach, especially in severe conditions such as inflammatory bowel disease (IBD). The purpose of our study was to develop a personalized probiotic strategy and assess its efficacy in a murine model of intestinal inflammation. Commensal bacterial strains were isolated from the feces of healthy mice and then administered back to the host as a personalized treatment in dextran sodium sulfate (DSS)-induced colitis. Colonic tissues were collected for histological analysis and to investigate inflammatory markers such as Il-1β, Il-6, TGF-β, and Il-10, and the enzyme myeloperoxidase as a neutrophil marker. The group that received the personalized probiotic showed reduced susceptibility to DSS-colitis as compared to a commercial probiotic. This protection was characterized by a lower disease activity index and reduced histopathological damage in the colon. Moreover, the personalized probiotic was more effective in modulating the host immune response, leading to decreased Il-1β and Il-6 and increased TGF-β and Il-10 expression. In conclusion, our study suggests that personalized probiotics may possess an advantage over commercial probiotics in treating dysbiotic-related conditions, possibly because they are derived directly from the host's own microbiota.en
dc.description.affiliationDepartment of Food and Nutrition School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationDivision of Gastroenterology Department of Pediatrics BC Children's Hospital and the University of British Columbia
dc.description.affiliationUnespDepartment of Food and Nutrition School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.sponsorshipCrohn's and Colitis Canada
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipCanadian Institutes of Health Research
dc.description.sponsorshipIdCrohn's and Colitis Canada: -
dc.description.sponsorshipIdFAPESP: 2014/15129-1
dc.description.sponsorshipIdCanadian Institutes of Health Research: PJT 148846 and 159528
dc.identifierhttp://dx.doi.org/10.3390/nu10111684
dc.identifier.citationNutrients, v. 10, n. 11, 2018.
dc.identifier.doi10.3390/nu10111684
dc.identifier.issn2072-6643
dc.identifier.scopus2-s2.0-85056262710
dc.identifier.urihttp://hdl.handle.net/11449/188331
dc.language.isoeng
dc.relation.ispartofNutrients
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectBifidobacterium
dc.subjectcolitis
dc.subjectIBD
dc.subjectLactobacillus
dc.subjectmicrobiota
dc.subjectmicrobiota biobank
dc.subjectpersonalized probiotic
dc.titleIsolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probioticsen
dc.typeArtigo
unesp.author.orcid0000-0001-9057-9041 0000-0001-9057-9041[1]

Arquivos

Coleções

Artigos - Alimentos e Nutrição - FCFAR